Portal:AOP/FeaturedPathways
From WikiPathways
(Difference between revisions)
| Line 1: | Line 1: | ||
{| style="margin: 10px" | {| style="margin: 10px" | ||
| - | |width=100px; cell padding=50px|{{#pwImage:Pathway: | + | |width=100px; cell padding=50px|{{#pwImage:Pathway:WP4891|250px||COVID-19 AOP (Homo sapiens)}} |
| + | |width=100px|{{#pwImage:Pathway:WP4945|250px||Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4944|250px||Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP4914|250px||Adverse Outcome Pathway (AOP) for Mitochondrial Complex 1 (C1) inhibition (Homo sapiens) | ||
| + | }} | ||
| + | |- | ||
|width=100px|{{#pwImage:Pathway:WP3980|250px||Protein alkylation leading to liver fibrosis (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3980|250px||Protein alkylation leading to liver fibrosis (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP3624|250px||Lung fibrosis (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3624|250px||Lung fibrosis (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP3632|250px||Lung fibrosis (Mus musculus)}} | |width=100px|{{#pwImage:Pathway:WP3632|250px||Lung fibrosis (Mus musculus)}} | ||
| + | |width=100px|{{#pwImage:Pathway:WP3997|250px||Epilepsy Adverse Outcome Pathway (Homo sapiens)}} | ||
|- | |- | ||
|width=100px|{{#pwImage:Pathway:WP4010|250px||Liver steatosis AOP (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP4010|250px||Liver steatosis AOP (Homo sapiens)}} | ||
| Line 18: | Line 24: | ||
|width=100px|{{#pwImage:Pathway:WP3890|250px||Nanomaterial induced inflammasome activation (Homo sapiens)}} | |width=100px|{{#pwImage:Pathway:WP3890|250px||Nanomaterial induced inflammasome activation (Homo sapiens)}} | ||
|width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | |width=100px|{{#pwImage:Pathway:WP3181|250px||Nanoparticle-mediated activation of receptor signaling (Bos taurus)}} | ||
| - | |||
|} | |} | ||
Revision as of 10:20, 7 August 2020
|
Image does not exist COVID-19 AOP (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to parkinsonian motor deficits (Homo sapiens) |
Image does not exist Mitochondrial Complex I inhibition leading to chemical induced fanconi syndrome (Homo sapiens) |
Image does not exist Adverse Outcome Pathway (AOP) for Mitochondrial Complex 1 (C1) inhibition (Homo sapiens) |
|
Image does not exist Protein alkylation leading to liver fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Homo sapiens) |
Image does not exist Lung fibrosis (Mus musculus) |
Image does not exist Epilepsy Adverse Outcome Pathway (Homo sapiens) |
|
Image does not exist Liver steatosis AOP (Homo sapiens) |
Image does not exist Steatosis AOP (Homo sapiens) |
Image does not exist Selective serotonin reuptake inhibitors lead to several adverse outcomes (Homo sapiens) |
Image does not exist Gastric ulcer formation (Homo sapiens) |
|
Image does not exist Nanoparticle-mediated activation of receptor signaling (Homo sapiens) |
Image does not exist Nanomaterial induced apoptosis (Homo sapiens) |
Image does not exist Nanoparticle triggered regulated necrosis (Homo sapiens) |
Image does not exist Nanoparticle triggered autophagic cell death (Homo sapiens) |
|
Image does not exist Overview of nanoparticle effects (Homo sapiens) |
Image does not exist Nanomaterial induced inflammasome activation (Homo sapiens) |
Image does not exist Nanoparticle-mediated activation of receptor signaling (Bos taurus) |
List of featured pathways:
